These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 24291466

  • 1. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
    Chiu WH, Carlsson T, Depboylu C, Höglinger GU, Oertel WH, Ries V.
    Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
    Chiu WH, Depboylu C, Hermanns G, Maurer L, Windolph A, Oertel WH, Ries V, Höglinger GU.
    Neuropharmacology; 2015 Aug; 95():367-76. PubMed ID: 25839898
    [Abstract] [Full Text] [Related]

  • 3. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
    Marin C, Bonastre M, Mengod G, Cortés R, Giralt A, Obeso JA, Schapira AH.
    Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
    [Abstract] [Full Text] [Related]

  • 4. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H, Takahata K, Okano M, Ishikawa T, Satoyoshi H, Nishimura T, Hoshino N, Muraoka S.
    Behav Brain Res; 2018 Jul 16; 347():350-359. PubMed ID: 29526790
    [Abstract] [Full Text] [Related]

  • 5. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS, Choi HS, Zhao TT, Suh KH, Kwon IH, Choi SO, Lee MK.
    Arch Pharm Res; 2013 Jun 16; 36(6):759-67. PubMed ID: 23539311
    [Abstract] [Full Text] [Related]

  • 6. Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson's disease.
    Shin KS, Zhao TT, Choi HS, Hwang BY, Lee CK, Lee MK.
    Brain Res; 2014 Jun 03; 1567():57-65. PubMed ID: 24747613
    [Abstract] [Full Text] [Related]

  • 7. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY, Park HJ, Ahn YH, Lee PH.
    J Neurochem; 2009 Nov 03; 111(4):1042-50. PubMed ID: 19765187
    [Abstract] [Full Text] [Related]

  • 8. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1999 Feb 03; 155(2):204-20. PubMed ID: 10072296
    [Abstract] [Full Text] [Related]

  • 9. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 03; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul 03; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 11. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
    Sader-Mazbar O, Loboda Y, Rabey MJ, Finberg JP.
    Br J Pharmacol; 2013 Nov 03; 170(5):999-1013. PubMed ID: 23992249
    [Abstract] [Full Text] [Related]

  • 12. Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
    Shimazu S, Takahata K, Tamashiro A, Yoneda F, Iida Y, Saji H.
    J Neural Transm (Vienna); 2003 Aug 03; 110(8):871-83. PubMed ID: 12898343
    [Abstract] [Full Text] [Related]

  • 13. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L, Deng M, Zhang S, Lu S, Gui X, Fang Y.
    Biomed Pharmacother; 2017 Oct 03; 94():666-678. PubMed ID: 28787702
    [Abstract] [Full Text] [Related]

  • 14. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
    Prinz A, Selesnew LM, Liss B, Roeper J, Carlsson T.
    Exp Neurol; 2013 Oct 03; 248():236-45. PubMed ID: 23810738
    [Abstract] [Full Text] [Related]

  • 15. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
    Waldmeier PC, Spooren WP, Hengerer B.
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec 03; 362(6):526-37. PubMed ID: 11138845
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotective actions of selegiline.
    Ebadi M, Sharma S, Shavali S, El Refaey H.
    J Neurosci Res; 2002 Feb 01; 67(3):285-9. PubMed ID: 11813232
    [Abstract] [Full Text] [Related]

  • 17. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V, Sosti V, Rubio A, Barbanoj M, Rodríguez-Alvarez J, Kulisevsky J.
    Eur J Pharmacol; 2007 Dec 08; 576(1-3):83-90. PubMed ID: 17888901
    [Abstract] [Full Text] [Related]

  • 18. The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
    Prat G, Pérez V, Rubi A, Casas M, Unzeta M.
    J Neural Transm (Vienna); 2000 Dec 08; 107(4):409-17. PubMed ID: 11215752
    [Abstract] [Full Text] [Related]

  • 19. Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb.
    Winner B, Geyer M, Couillard-Despres S, Aigner R, Bogdahn U, Aigner L, Kuhn G, Winkler J.
    Exp Neurol; 2006 Jan 08; 197(1):113-21. PubMed ID: 16246330
    [Abstract] [Full Text] [Related]

  • 20. Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
    Adams CE, Hoffman AF, Hudson JL, Hoffer BJ, Boyson SJ.
    Exp Neurol; 1994 Dec 08; 130(2):261-8. PubMed ID: 7867755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.